|Home | About | Journals | Submit | Contact Us | Français|
In the present study we identified a novel gene, Homo Sapiens Chromosome 1 ORF109 (c1orf109, GenBank ID: NM_017850.1), which encodes a substrate of CK2. We analyzed the regulation mode of the gene, the expression pattern and subcellular localization of the predicted protein in the cell, and its role involving in cell proliferation and cell cycle control.
Dual-luciferase reporter assay, chromatin immunoprecipitation and EMSA were used to analysis the basal transcriptional requirements of the predicted promoter regions. C1ORF109 expression was assessed by western blot analysis. The subcellular localization of C1ORF109 was detected by immunofluorescence and immune colloidal gold technique. Cell proliferation was evaluated using MTT assay and colony-forming assay.
We found that two cis-acting elements within the crucial region of the c1orf109 promoter, one TATA box and one CAAT box, are required for maximal transcription of the c1orf109 gene. The 5′ flanking region of the c1orf109 gene could bind specific transcription factors and Sp1 may be one of them. Employing western blot analysis, we detected upregulated expression of c1orf109 in multiple cancer cell lines. The protein C1ORF109 was mainly located in the nucleus and cytoplasm. Moreover, we also found that C1ORF109 was a phosphoprotein in vivo and could be phosphorylated by the protein kinase CK2 in vitro. Exogenous expression of C1ORF109 in breast cancer Hs578T cells induced an increase in colony number and cell proliferation. A concomitant rise in levels of PCNA (proliferating cell nuclear antigen) and cyclinD1 expression was observed. Meanwhile, knockdown of c1orf109 by siRNA in breast cancer MDA-MB-231 cells confirmed the role of c1orf109 in proliferation.
Taken together, our findings suggest that C1ORF109 may be the downstream target of protein kinase CK2 and involved in the regulation of cancer cell proliferation.
CK2 (formerly known as casein kinase II) is a ubiquitous, highly conserved and messenger-independent protein serine/threonine kinase composed of two catalytic α subunits (αα, αα′, or α′α′) and two regulatory β subunits in eukaryotic cells [1,2]. To date, more than 300 potential substrates located in various compartments of the cell have been identified . A unique property of CK2 is that it can use both ATP and GTP as the phosphate donor. CK2 plays a global role in cell cycle progression, cell growth and proliferation, cell survival and cell death [4-8]. Lack of any on/off regulatory mechanism, CK2 is constitutively active in cells. It was postulated that the intracellular dynamic shuttling of CK2 might represent a general mechanism of its regulation . Emerging evidence shows that CK2 signaling is dysregulated in many human diseases, including cancer. CK2 is upregulated in all cancers that have been examined [10-12]. Although the kinase has been studied for over 50years, its physiological role and regulatory mechanism have not been thoroughly elucidated.
The identification of cancer associated molecular alterations has exploited many insights into the roles of oncogenes or tumor suppressor genes in cancer progression. Previously, we obtained an unknown cDNA fragment named OPB7-1, which had different expression levels in two human lung cancer cell lines with different metastasis potentials . Next, we mapped it to human chromosome 1p34 by radiation hybridization mapping . Bioinformatic methods, RACE (rapid amplification of cDNA ends) and sequencing were performed to obtain the 3′ and 5′ ends of the gene from normal human lung tissue. BLASTN results revealed that this cDNA sequence was homologous with Homo Sapiens Chromosome 1 ORF109 (c1orf109, GenBank ID: NM_017850.1). The mRNA sequences of c1orf109 are divided into five exons by four introns. The hypothetical protein C1ORF109 consists of 203 amino acids, and the predicted molecular weight and pI are 23.4kD and 5.47 respectively. However, no functional study on c1orf109 has been reported.
In order to investigate the biological function of c1orf109 in the cell, we analyzed the putative promoter and the biological features using bioinformatic tools. Meanwhile, we identified the existence and subcellular location of endogenous C1ORF109 protein. In addition, we also investigated the role of c1orf109 gene involving in cancer cell proliferation.
HEK293, HeLa, MDA-MB-231 and Hs 578T cells were purchased from American Type Culture Collection (ATCC). All cells were cultured in accordance with the recommendations of ATCC. Oligonucleotides were synthesized by Invitrogen. Anti-Flag M5 and anti-C1ORF109 antibodies were from Sigma-Aldrich. Anti-phosphoserine antibodies were from BD. Anti-PCNA and anti-cylcinD1 antibodies were from Abcam plc.
PCR amplification was performed with c1orf109-specific primers to clone the putative c1orf109 5′ proximal promoter. An approximately 1.8kb fragment that contained the immediate 5′-flanking sequence of the putative c1orf109 promoter (Genbank ID: AC104336) was amplified. This 1.8kb fragment was subcloned into the pGL3-basic vector (Promega). The complete sequence was identified with sequencing by the 3130 Genetic Analyzer (Applied Biosystems). Progressive 5′ deletions and site-directed mutations of putative cis-elements were achieved by PCR with the primers listed in Table Table11.
HEK293 cells were transiently transfected with various c1orf109 promoter-luciferase constructs by Lipofectamine 2000 Reagent (Invitrogen). About 2×105 HEK293 cells in each well of a 24-well plate were transfected with 1.0μg of each pGL3-c1orf109 promoter construct plus 50ng of the phRL-SV40 vector. The firefly luciferase activity was examined 24hr after transfection using the Dual-Luciferase Reporter Assay System (Promega). Renilla luciferase activity was used as an internal control. Each experiment was repeated at least three times.
EMSA was performed using Chemiluminescent EMSA Kit (Beyotime). Briefly, 5μg of nuclear extract was incubated with 10ng of each biotin-labeled probe in binding buffer for 30min at room temperature. Meanwhile, reactions contained a 100-fold excess of the same unlabeled probe, and other unrelated probes were used to determine specific and nonspecific binding. Furthermore, specific antibodies against Sp1 for supershift assay were performed in other reactions. Then the reaction mixtures were separated in a 4% nondenaturing polyacrylamide gel in 0.5×TBE at 60V for 2 hours. Then the DNA/protein complex was transferred to nylon membrane, conjugated with Streptavidin-HRP, visualized with ECL, and detected by the Odyssey Fc Imaging System. The probes used for EMSA are listed in Table I.
ChIP assays were performed as described previously  with slight modification. About 1×107 cells were fixed with 0.8% formaldehyde for 10min, lysed in 150μl Buffer A (10mM Tris–HCl, pH 8.0, 10mM NaCl, 0.2% NP40) for 10min on ice. Spin down the precipitation and resuspend in 1ml Buffer B (50mM Tris–HCl, pH 8.0, 10mM EDTA, 1% SDS). The lysate was fragmented by sonication to yield fragments between 200bp and 1000bp, and then centrifuged at 13,000g for 15min at 4°C. The supernatant was whole cell extract (WCE). Three μg of anti-Sp1 antibody was added into tubes containing 200μl WCE plus 300μl Buffer C (16.7mM Tris–HCl, pH 8.0, 167mM NaCl, 1.2mM EDTA, 0.01% SDS, 1.1% Triton X-100). After incubation, the antibody complexes were collected with protein A agarose beads and subjected to serial washes. Cross-linked chromatin was reversed at 65°C in the presence of 200mM NaCl for 5hr. The DNA fragments were then purified using chloroform-isoamyl alcohol. The PCR primers used to amplify the endogenous c1orf109 promoter were listed in Table Table1.1. PCR products were then run on an agarose gel and photographed. Meanwhile, DNA fragment extracted from 200μl WCE was saved as positive control. Another pair of primers (ChIP InpF/R) that amplified DNA sequences from ~60bp to ~900bp downstream of the the transcriptional start site (TSS) was used as negative control.
The phosphorylation of the recombinant full-length C1ORF109 protein by CK2 in vitro was detected using the Casein Kinase 2 Assay Kit (Upstate). This assay is based on phosphorylation of a CK2 substrate using the transfer of the γ-phosphate of [γ-32P]-ATP by CK2 kinase. The phosphorylated substrate was separated from the residual [γ-32P]-ATP using P81 phosphocellulose paper, and [32P] incorporation into the substrate was measured using a scintillation counter and expressed as the calculated pmol phosphate incorporated into CK2 substrate peptide/min/ng of CK2.
To further verify C1ORF109 phosphorylation by CK2, about 0.1μg of recombinant full-length C1ORF109 protein was incubated with human CK2 (Upstate) in Hybrid Buffer (25mM Tris–HCl, pH 7.5, 25mM NaCl, 5mM MgCl2, 1mM DTT) and 0.1mM ATP plus 4μCi [γ-32P]-ATP (3000Ci/mM) for 30min at 25°C , and fractionated by SDS-PAGE. Dried Coomassie blue-stained gels were analyzed by the Storage Phosphor System (Cyclone).
siRNA oligonucleotides were synthesized, and the sequences of the siRNA for human c1orf109 was 5′-UGGAAUGGUUGCAGGAUAUTT3′. A non-targeting siRNA, 5′-UUCUCCGAACGUGUCACGUTT-3′, was used as a negative control. MDA-MB-231 cells were transfected with siRNA oligonucleotides using Lipofectamine 2000 Reagent (Invitrogen). Wild type c1orf109 was cloned into the pcDNA3.1-Flag vector. Hs578T cells were stably transfected with pcDNA3.1 or c1orf109 using Lipofectamine 2000 Reagent followed by G418 (Merck) selection.
Proliferation was analyzed using MTT assay and colony-forming assay. In the MTT assay, 3×103 cells were plated in 100μl media per well in 96-well dishes, the medium was removed and replaced with 100μl fresh culture medium containing 1.2mM MTT at the indicated time points. The reaction was incubated at 37°C for 4hr. Next, 100μl of SDS-HCl solution (10% SDS, 0.01M HCl) was added to each well. After incubation at 37°C for 4hr, each sample was mixed using a pipette, and absorbance was read at 570nm. In the colony-forming assay, cells were plated in 6-well dishes at 500 cells/well. Every 4days, the medium was replaced with fresh medium. When the colonies were clearly visible (after about two weeks), they were stained with crystal violet and counted.
Cells were lysed in RIPA lysis buffer (50mM Tris–HCl, pH 7.4, 150mM NaCl, 1% NP-40, 0.1% SDS, and 0.5% sodium deoxycholate) containing 10μg/ml aprotinin, 10μg/ml leupeptin, and 1mM PMSF. Equal amounts of cell lysates were electrophoresed in 12% SDS-polyacrylamide gels, and proteins were transferred to a nitrocellulose membrane. Membranes were blocked with 5% defatted milk and probed with the indicated primary antibodies, and were incubated with secondary antibodies conjugated with horseradish peroxidase. The ECL western blotting analysis system was used to detect the substrates.
Cells were harvested and fixed in 70% ice-cold ethanol for 10 minutes and incubated with RNase A (100μg/ml) and propidium iodide (50μg/ml) for 30 minutes, and 1×104 cells from each sample were subjected to fluorescence-activated cell sorter scan (Becton Dickinson) analysis.
Statistical analysis was conducted using the two-tailed Student’st test and one-way ANOVA where appropriate. The data were presented as means±S.D. obtained from three independent experiments. Results were considered to be statistically significant at P<0.05.
Because c1orf109 is a novel gene, its mechanism of regulation is unclear. To analyze the putative promoter of the human c1orf109 gene, an approximately 1.8kb DNA sequence located upstream of the TSS was cloned as described in the Methods and Materials section. Nucleotide sequence analysis of the 5′ flanking region of the c1orf109 gene using MatInspector online software revealed the presence of one TATA box (at −48bp) and three CAAT boxes (at −135bp, -200bp, -293bp respectively), as shown in Figure Figure1A.1A. Progressive 5′ deletions of the c1orf109 gene promoter constructs were generated to identify transcriptional regulatory elements (Figure (Figure1B).1B). All truncated constructs were transiently transfected into HEK293 cells. Firefly luciferase activity was normalized by co-transfection with a Renilla luciferase vector. Meanwhile, the promoter-less pGL3-basic vector was used as a negative control. Significant luciferase activity was observed after transfection of the construct containing the proximal 93bp region upstream of the TSS. Transfection of sequences further upstream, from −177 to −428bp, resulted in a significant increase in promoter activity, whereas transfection of the proximal 41bp did not generate luciferase activity. The results indicate that the region from −41 to −177bp contains positive regulatory elements essential for achieving maximal c1orf109 promoter activity.
To further identify the functional significance of the potential transcription factor binding sites within the region of −41 to −177bp, including the putative CAAT boxes and TATA box, serial site-directed mutation constructs were used to analyze their effects on luciferase activity in HEK293 cells. Disruption of the CAAT I and TATA box sites caused impaired promoter activity by approximately 44 to 47 percent. In contrast, mutations of the CAAT box II or CAAT box III sites did not affect c1orf109 promoter activity (Figure (Figure2).2). Therefore, we conclude that CAAT box I and TATA box act as important cis-acting elements within the c1orf109 promoter.
Sp1 is a transcription factor that either enhances or represses the activity of promoters of genes involved in differentiation, cell cycle progression, and oncogenesis . The presence of several potential GC boxes suggested that transcriptional factor Sp1 may be involved in the transcriptional regulation of c1orf109 gene. To confirm whether Sp1 directly interact with c1orf109 promoter, chromatin immunoprecipitation (ChIP) assay was performed. HeLa cells were fixed, lysed and fragmented as described in methods and materials. DNA was optimally sheared with a distribution of fragments from 200 to1000 bp, as shown in Figure Figure3A.3A. Immunoprecipitation of DNA/protein complexes using antibodies against Sp1 was followed by PCR amplification. As shown in Figure Figure3B,3B, anti-Sp1 antibody was capable of immunoprecipitating the c1orf109 promoter fragment containing the GC box 4 (Figure (Figure3B,3B, lane 9); however, primers ChIP InpF/R failed to produce a PCR product (Figure (Figure3B,3B, lanes 4, 8 and 12), indicating that Sp1 directly interacted with c1orf109 promoter region.
To detect whether Sp1 interacts directly with the potential GC boxes, an electrophoretic mobility shift assay (EMSA) was performed. Oligonucleotides corresponding to the binding sites for Sp1 in the c1orf109 promoter were designed (Table I). According to the results of EMSA (Figure (Figure3C),3C), the mobility of labeled probes corresponding to GC box 4 was shifted in the presence of nuclear protein prepared from HeLa cells. The binding specificity of each probe was verified by supershift when we added anti-Sp1 anitibody or excessive unlabeled oligonucleotide competitors. These data suggest that the CAAT box and TATA box are required for achieving the basal transcription of the c1orf109 gene. The 5′ flanking region of the c1orf109 gene could bind specific transcription factors and Sp1 may participate in the regulation of transcriptional expression of the gene. The activation of transcription by CAAT box and TATA box may be further modulated by GC box.
Previously, we have reported that c1orf109 exhibited an increased expression in lung cancer tissues compared to paired adjacent non-tumor tissues using in situ hybridization with specific RNA probes . To further identify the existence and expression pattern of the putative protein C1ORF109 in the cell, the expression of c1orf109 in 11 breast cancer cell lines and a melanoma cell line were detected by immunoblotting. Meanwhile, a non-tumorigenic epithelial cell line (MCF10A)  and an immortalized human keratinocyte cell line (HaCaT)  were used as control. As shown in Figure Figure4A,4A, C1ORF109 levels were upregulated in tumorigenic cell lines compared to the control, especially in the cell lines derived from metastatic sites, such as the cell lines derived from pleural effusion (MDA-MB-436, MDA-MB-453, MDA-MB-231, MDA-MB-435s, T-47D, and SK-BR-3), and ascites (ZR-75-30). Furthermore, we also found that C1ORF109 was overexpressed in hepatocellular cancer tissues compared to paired adjacent non-tumorous tissues by quantitative real-time PCR (qRT-PCR) (see Additional file 1). These findings indicate that increased expression of C1ORF109 may be involved in cancer progression.
The subcellular localization of the C1ORF109 protein was also examined using immunofluorescence. cDNA was subcloned into a pCMV-Flag vector. Hs578T cells were cultured on a round coverslip and transiently transfected with pCMV-Flag-c1orf109. A mock vector was used as negative control. The cells were subsequently fixed, incubated with TRITC-labeled antibodies, and analyzed by confocal microscopy. Positive signals were found mainly in the nucleus and cytoplasm. No signal was detected in the control cells (Figure (Figure4B).4B). To confirm further the subcellular localization of C1ORF109, an immune colloidal gold assay was performed in NIH3T3 cells that stably expressed V5 tagged C1ORF109. The samples were analyzed by transmission electron microscope, and the results showed that the colloidal gold particles (diameter, ~15nm) mainly localized to the nucleus and cytoplasm (Figure (Figure2C).2C). In addition, the subcellular localization of endogenous C1ORF109 was detected in HeLa cells using anti-C1ORF109 antibodies (Figure (Figure2D).2D). These data indicate that C1ORF109 protein is mainly located in the nucleus and cytoplasm.
Since c1orf109 has been shown to be involved in cancer progression, we focused on the biological functions of c1orf109 in the cell. To determine the functional domain of C1ORF109 at the molecular level, the PROSITE method was used to analyze the amino acid sequence, and three potential CK2 phosphorylation sites at serines 104, 134 and 182 were found. Therefore, C1ORF109 is predicted to be a phosphoprotein. The full-length C1ORF109 purified from HEK293 cells was recognized by anti-phosphoserine antibodies (Figure (Figure5A).5A). Moreover, treatment of C1ORF109 immunoprecipitated from HEK293 cells with calf intestinal phosphatase (CIP) resulted in different electrophoretic mobility compared with untreated C1ORF109 (Figure (Figure5B).5B). Together, these data imply that C1ORF109 is a phosphoprotein in eukaryotic cells.
To test whether C1ORF109 is a substrate of protein kinase CK2, the full-length C1ORF109 purified from HEK293 cells was incubated with human CK2, [γ-32P]-ATP in vitro, and the CPM was subsequently read in a scintillation counter. To exclude the influence of PKA, a PKA inhibitor cocktail was added to the reaction system. The results indicate that C1ORF109 is efficiently phosphorylated by CK2 in vitro (Figure (Figure5C).5C). Meanwhile, C1ORF109 phosphorylation was abolished by heparin, which is a specific inhibitor of protein kinase CK2 (Figure (Figure5D).5D). Next, serines 104, 134 and 182 were converted into nonphosphorylatable alanine residues yielding a mutant C1ORF109. C1ORF109Mut cannot be phosphorylated by CK2 in vitro (Figure (Figure5E).5E). These findings suggest that C1ORF109 is specifically phosphorylated by CK2 in vitro, and that it is a substrate of the protein kinase CK2.
CK2, a ubiquitous protein serine/threonine kinase with hundreds of substrates, is essential for the modulation of cell growth and proliferation. Since C1ORF109 has been identified to be a substrate of CK2, it might play a role in the modulation of cell proliferation. To verify this postulation, MDA-MB-231 cells, which express endogenous C1ORF109 at high levels, were transiently transfected with c1orf109-siRNA to knock down endogenous C1ORF109 and showed a reduction in cell viability (P<0.05, Figure Figure6A).6A). However, Hs578T cells, which express low levels of endogenous C1ORF109, were stably transfected to overexpress exogenous C1ORF109 and showed a 5-fold increase in colony number in colony-forming assays (P<0.05, Figure Figure6B6B).
The D-type cyclins (Dl, D2 and D3) are key governors of the progression from G1 to S phase of the mammalian cell cycle. These three D-type cyclins are expressed in overlapping and apparently redundant fashion in proliferating tissues [20,21]. PCNA, a regulator of DNA replication and cell cycle control, is a well-defined cell proliferation parameter [22,23]. We tested the effect of C1ORF109 overexpression or depletion on the expression levels of PCNA and cyclinD1. Downregulation of PCNA and cyclinD1 were detected in C1ORF109-depleted cells. Meanwhile, Hs578T cells stably expressing exogenous C1ORF109 showed increased expression of PCNA and cyclinD1 (Figure (Figure6C).6C). In addition, the effect of c1orf109 on cell cycle distribution was examined by flow cytometry. Cell cycle analysis of MDA-MB-231 cells transfected with c1orf109-siRNA showed an increase in G1 phase and a reduction in DNA synthetic activity (S phase), whereas stably expressing exogenous C1ORF109 in Hs578T cells resulted in fewer cells accumulating in G1 phase compared to the control (Figure(Figure6D).6D). These results indicate that upregulation of c1orf109 in breast cancer cells could promote cancer cell proliferation in vitro, which is mainly due to the acceleration of G1 to S phase transition.
In conclusion, our experiments show that the unknown gene c1orf109 encodes a CK2 substrate and is involved in the modulation of cell proliferation. More work will be required to identify the molecular mechanisms by which CK2 regulates the expression of C1ORF109 and then affects cell proliferation.
The authors declare that they have no competing interest.
SSL and YL designed the study and drafted the manuscript. SSL performed the transcriptional analyses, qRT-PCR, MTT assay and colony forming assay. HXZ, HDJ and JH carried out the immunofluorescence and immunoelectron microscopy with colloidal gold. YPQ, LY and YZ helped to collect the data. All authors read and approved the final manuscript.
The expression of c1orf109 mRNA in hepatocellular carcinomas (HCCs) detected by quantitative real-time PCR.
We thank Ji-lai Liu, Jie Su, and Zhu Wang for generating c1orf109 promoter-luciferase constructs. This work was supported by the National Natural Science Foundation of China (No.30170516 and No.30871271).